Heck Capital Advisors LLC Takes $185,000 Position in CVS Health Co. (NYSE:CVS)

Heck Capital Advisors LLC acquired a new stake in CVS Health Co. (NYSE:CVS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,129 shares of the pharmacy operator's stock, valued at approximately $185,000.

Other large investors have also added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of CVS Health in the fourth quarter valued at approximately $839,574,000. Capital World Investors boosted its stake in CVS Health by 26.6% in the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after purchasing an additional 12,819,148 shares during the period. Davis Selected Advisers grew its holdings in CVS Health by 2,998.1% in the 4th quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock valued at $511,115,000 after buying an additional 11,018,438 shares in the last quarter. Dodge & Cox increased its position in CVS Health by 11.2% during the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after buying an additional 7,075,209 shares during the period. Finally, Pzena Investment Management LLC lifted its holdings in shares of CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after buying an additional 6,475,271 shares in the last quarter. Institutional investors own 80.66% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CVS. JPMorgan Chase & Co. upped their price target on shares of CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research note on Tuesday, February 18th. Cantor Fitzgerald raised shares of CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Robert W. Baird raised their price objective on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Piper Sandler upped their price objective on shares of CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a research report on Friday, March 21st. Finally, Argus set a $77.00 target price on shares of CVS Health in a report on Tuesday, February 18th. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $74.94.

Insider Transactions at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This trade represents a 47.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.22% of the company's stock.

CVS Health Price Performance

Shares of CVS Health stock traded up $0.27 during midday trading on Thursday, hitting $62.72. 10,632,833 shares of the company traded hands, compared to its average volume of 11,290,342. The stock has a market cap of $79.34 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 0.98 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm's fifty day moving average price is $65.76 and its 200-day moving average price is $59.48. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same period in the prior year, the business earned $1.31 earnings per share. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, sell-side analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were given a $0.665 dividend. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 4.24%. CVS Health's dividend payout ratio is presently 63.48%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.